Parkinson's Disease Neuroprotection Clinical Centers

帕金森病神经保护临床中心

基本信息

批准号：
7564952
负责人：
JOHN FANG
金额：
$ 6.46万
依托单位：
VANDERBILT UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2002
资助国家：
美国
起止时间：
2002-09-15 至 2012-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7564952
关键词：
Academic Medical Centers Acute Adult Adverse effects Advertisements Advertising Advisory Committees Affect African American Agonist Agreement Alaska Native Alcohols Algorithms Amantadine American American Indians Americas Animal Model Animals Antioxidants Antiphospholipid Syndrome Apoptotic Appendix Applications Grants Appointment Archives Area Asians Attenuated Authorization documentation Autonomic nervous system Award Awareness Benefits and Risks Biological Biological Assay Biological Markers Blood Body of uterus Boston Botox Botulinum Toxin Type A Botulinum Toxins Boxing Brothers Budgets Burn injury COMT gene California Carbidopa Cardiovascular system Caring Carpal Tunnel Syndrome Case Report Form Catechol O-Methyltransferase Catechols Categories Cell Death Cell Line Cellular Stress Central Nervous System Diseases Cerebrospinal Fluid Cerebrum Certification Cervical Cervical Dystonia Chairperson Chemistry Child Cities Civil Rights Class Classification Clinic Clinical Clinical Pharmacology Clinical Protocols Clinical Research Clinical Skills Clinical Trials Clonazepam Code Collaborations Collection Communities Complement Computers Confidential Information Confidentiality Conflict of Interest Consent Forms Contingency Fund Controlled Clinical Trials Contusions Corpus Callosum Cross-Over Studies Crossover Design Daily Data Data Analyses Data Collection Data Protection Databases Deep Brain Stimulation Deterioration Development Development Plans Dextromethorphan Diagnosis Diagnostic Direct Costs Disabled Persons Discipline of Nursing Disclosure Discrimination Disease Disease Association Disease Progression District of Columbia Doctor of Medicine Dopa Dopamine Dopamine Agonists Dose Double-Blind Method Drug Addiction Drug Kinetics Dysautonomias Dyskinetic syndrome Dystonia Early treatment Edema Education Elan brand of botulinum toxin type B Electron Spin Resonance Spectroscopy Electronics Elements End Point Energy Metabolism Enrollment Ensure Environment Epilepsy Equipment Estradiol Ethnic Origin Evaluation Event Excitatory Amino Acid Antagonists Exclusion Criteria Exhibits Face Facilities and Administrative Costs Faculty Failure Family Physicians Federal Government Female Financial compensation Focal Dystonias Follow-Up Studies Foundations France Free Radicals Fringe Benefit Funding Future GDNF gene Gender Gender Role Gene Transfer General Hospitals Genes Genetic Goals Grant Grant Review Guidelines Health Health Policy Healthcare Hispanics Hospitals House Staffs Human Human Resources Huntington Disease Hypertension Hypotension Immigration Income Individual Informed Consent Injectable Injection of therapeutic agent Injury Inpatients Institutes Institution Instruction Intelligence Internal Medicine International International Aspects Intervention Joints Jordan Journals Label Laboratories Laboratory Study Language Last Name Lead Lebanon Legal Guardians Letters Levodopa Licensing Life Liquid substance Literature Lobbying Location Longitudinal Studies Lower Extremity Magnetic Resonance Imaging Manuals Manuscripts Marketing Maryland Measures Mediating Mediation Medical Medical Records Medical center Medicine Metabolic Pathway Methods Migraine Minor Minority Minority Groups Mississippi Modeling Monitor Morus Motor Motor Neuron Disease Movement Movement Disorders Multicenter Studies Multicenter Trials Multiple Sclerosis Multiple System Atrophy Mus Muscle N-Methyl-D-Aspartate Receptors Names Native Hawaiian or Other Pacific Islander Neurodegenerative Disorders Neuroleptic Malignant Syndrome Neurologic Neurological status Neurologist Neurology Neuropathy Neuropharmacology Neuroprotective Agents None or Not Applicable Not Hispanic or Latino Numbers Nurses Nursing Research Occipital lobe Octreotide Office Nursing Ohio Operative Surgical Procedures Oral Oral cavity Orphan Outcome Measure Outpatients Parents Parkinson Disease Parkinsonian Disorders Participant Patient Care Patient Recruitments Patient Selection Patients Pediatric Neurology Peer Review Pennsylvania Performance Persons Pharmaceutical Preparations Pharmacodynamics Pharmacologic Substance Pharmacotherapy Phase Phase I Clinical Trials Philadelphia Physicians Physiologic pulse Physiological Pilot Projects Placebo Control Placebos Pluripotent Stem Cells Policies Positioning Attribute Positron-Emission Tomography Postmenopause Preparation Primary Health Care Principal Investigator Printing Procedures Professional Education Progress Reports Property Protein Kinase C Protocols documentation Provider Psychiatry Publications Publishing Pulse taking Purpose Quality of life Race Randomized Range Rare Diseases Rate Rattus Reaction Time Recombinant DNA Recombinants Recording of previous events Recruitment Activity Reflex action Registered nurse Regulation Rehabilitation therapy Relative (related person)Reporting Research Research Design Research Ethics Committees Research Infrastructure Research Misconduct Research Personnel Research Project Grants Research Subjects Research Support Resolution Resources Rights Riluzole Risk Risk Factors Roche brand of tolcapone Role Rosa Safety Saints Sampling Scanning Schools Science Screening procedure Selection Criteria Selegiline Services Severities Severity of illness Site Small Business Funding Mechanisms Small Business Innovation Research Grant Small Business Technology Transfer Research Smoke Sneddon Syndrome Solutions Source Specialist Specific qualifier value Specimen Standards of Weights and Measures Stem Cell Research Stroke Structure of subthalamic nucleus Suggestion Sumanirole Sumatriptan Superoxides Surgeon Surveys Suspension substance Suspensions Symptoms Syndrome System TPO gene Tachycardia Techniques Telefacsimile Telephone Tennessee Testing Thalamic structure Therapeutic Time Tissues Title Tongue Toxic effect Toxin Training Transplantation Travel Tremor United States United States Department of Veterans Affairs United States Dept. of Health and Human Services United States Food and Drug Administration United States National Institutes of Health United States Public Health Service Universities University Hospitals Update Upper arm Vertebrates Virus Wages Water Week Weight Withdrawal Woman Work Workplace Writing abstracting age discrimination austin base botulinum toxin type B clinical Diagnosis college computerized computing resources cost data acquisition day density design diaries dihydrexidine discount dopaminergic neuron dosage drug market editorial entacapone enzyme activity experience follow-up foot gabapentin gene therapy glial cell-line derived neurotrophic factor handicapping condition human fetus tissue human subject immunogenicity improved inhibitor/antagonist innovation instrument interest lamotrigine male medical schools member milacemide mouse model nerve stem cell nervous system disorder neural prosthesis neurogenetics neuroimaging neurophysiology neuroprotection neurotrophic factor novel patient safety peer performance site pilot trial placebo controlled study post-doctoral training prevent professor programs protective effect receptor repository research study response ropinirole sex size stroke rehabilitation synuclein tau Proteins thioether time use tolcapone transmission process

项目摘要

DESCRIPTION (provided by applicant): As outlined in this RFA (RFA-NS-02-010) announcement, the aims of this project are to create a clinical center for the conduct of future clinical trials of neuroprotection for Parkinson's disease. This site has three board-certified neurologists trained in movement disorders who will participate in this proposed project. Upon implementation of this project these neurologists will collaborate to conduct a pilot trial of an agent to prevent disease progression in PD. Subsequently, additional collaboration with the other clinical center sites will lead to at least one multicenter trial. This project will help to maintain a stable infrastructure for the administration of the clinical trial(s) in neuroprotection related to Parkinson's disease. In addition, the conduct of this type of clinical trial(s) will generate a sample of patients with early PD who may be willing to participate in genetic studies. Similarly, subjects may be willing to participate in studies to identify markers from blood or cerebrospinal fluid that may indicate disease presence or severity. This research may lead to a greater understanding of PD and better treatments.

描述（由申请人提供）：如本RFA（RFA-NS-02-010）公告中所述，该项目的目的是为帕金森氏病神经保护的未来临床试验创建临床中心。该站点有三位接受运动障碍培训的董事会认证的神经科医生，他们将参加该拟议项目。实施该项目后，这些神经科医生将合作进行试剂试验，以防止PD疾病进展。随后，与其他临床中心站点的额外合作将导致至少一项多中心试验。该项目将有助于维持与帕金森氏病有关的神经保护性临床试验的稳定基础设施。此外，这种类型的临床试验的行为将产生可能愿意参与遗传研究的早期PD患者样本。同样，受试者可能愿意参加研究，以鉴定可能表明疾病存在或严重程度的血液或脑脊液中的标记。这项研究可能会导致对PD和更好的治疗方法有更多的了解。